Surgical Outcomes in Patients with T4 Gastric Carcinoma

Kunisaki, Chikara; Akiyama, Hirotoshi; Nomura, Masato; Matsuda, Goro; Otsuka, Yuichi; Ono, Hideki; Nagahori, Yutaka; Takahashi, Mutsuo; Kito, Fumihiko; Shimada, Hiroshi

doi:10.1016/j.jamcollsurg.2005.10.020

Cited by 72 publications

(51 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven of these patients had recurrence in the liver caused by hematogenous metastasis. An association between hematogenous metastasis and differentiated-type adenocarcinoma has been reported [11,13], but was not evident in our study, perhaps because our study group was too small to reach statistical significance. Recurrence was associated with distant lymph node metastasis in three patients.…”

Section: Discussioncontrasting

confidence: 79%

Prognostic impact of venous invasion in stage IB node-negative gastric cancer

et al. 2014

View full text Add to dashboard Cite

Background Little is known about risk factors for recurrence in stage IB gastric cancer without lymph node metastasis. The aims of this study were to determine prognostic factors associated with long-term survival and to clarify patterns of recurrence. Methods We retrospectively reviewed the medical records of 130 patients with primary gastric cancer who underwent gastrectomy at Kitasato University East Hospital from 2001 through 2010 and analyzed clinicopathological characteristics associated with survival and patterns of recurrence. Results Of the 130 patients, 12 (9.2 %) had recurrence, among whom 10 (83 %) patients died. Four patients (3.1 %) died of other diseases. The 5-year overall survival rate was 89 %. Of the 12 patients with recurrence, 7 (58 %) had liver metastasis, 3 (25 %) had distant lymph-node metastasis, 2 (17 %) had peritoneal dissemination, and 1 (8.3 %) had locoregional recurrence. Patients with tumors more than 5 cm in diameter tended to have recurrence within 1 year. Patients who had recurrence more than 2 years after surgery tended to survive for longer than 5 years after recurrence. Moderate or marked venous invasion (v2 or v3) and age [65 years were significantly associated with relapse-free and overall survival on univariate analysis. On multivariate analysis, the only independent prognostic factor for relapse-free and overall survival was venous invasion. Conclusions Moderate or marked venous invasion (v2 or v3) is an independent predictor of relapse-free and overall survival in stage IB node-negative gastric cancer. Postoperative adjuvant chemotherapy, currently not given to this subgroup of patients, may improve the outcomes of patients with stage IB node-negative gastric cancer, particularly when accompanied by venous invasion.

show abstract

Section: Discussioncontrasting

confidence: 79%

Prognostic impact of venous invasion in stage IB node-negative gastric cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In previous reports, the overall survival rate for locally advanced gastric cancer patients was under 20% and approximately 30% for those who can undergo surgical resection. 24,25 In our study, only gastric cancer in the T4 stage at the initial diagnosis was an independent risk factor for recurrence, and 30.4% of the patients had recurrent disease. A more potent and aggressive adjuvant therapy is needed after curative resection of locally advanced gastric cancer (T4 gastric cancer).…”

Section: 김연지 등 위암 환자의 미세전이mentioning

confidence: 50%

The Detection of Messenger RNA for Carcinoembryonic Antigen and Cytokeratin 20 in Peritoneal Washing Fluid in Patients with Advanced Gastric Cancer

Kim

Chung

Choi

et al. 2017

Korean J Gastroenterol

View full text Add to dashboard Cite

“…10 As previously described, lymph node metastasis is reportedly an independent predictive factor in patients with serosa-negative gastric cancer. 11 Other researchers have also reported that lymph node metastasis is one of the most important risk factors for early or serosa-negative gastric cancer and that the N stage correlates with survival and recurrence rates. [12][13][14] N2 to N3 stage T1 tumors would have a more prognostic impact than T3 tumors without nodal metastases.…”

Section: Discussionmentioning

confidence: 95%

“…Ahn et al examined stage migration of 9998 gastric cancer patients between 1986 and 2006, and reported that the incidence of T1N2M0 was 1.2% (121/9998); T1N3M0 was 0.45% (45/9998); and T3N0M0 was 6.6% (662/9998), respectively. 11 We had only 52 patients who were classified with these categories and did not receive adjuvant chemotherapy during 2000 and 2010. Moreover, only 28 patients were classified with pT1N2-3 tumors.…”

Section: Discussionmentioning

confidence: 99%

Exploratory Analysis to Find Unfavorable Subset of Stage II Gastric Cancer for Which Surgery Alone Is the Standard Treatment; Another Target for Adjuvant Chemotherapy

Aoyama

Yoshikawa

Fujikawa

et al. 2014

International Surgery

View full text Add to dashboard Cite

The aim of the present study was to explore the unfavorable subset of patients with Stage II gastric cancer for whom surgery alone is the standard treatment (T1N2M0, T1N3M0, and T3N0M0). Recurrence-free survival rates were examined in 52 patients with stage T1N2-3M0 and stage T3N0M0 gastric cancer between January 2000 and March 2010. Univariate and multivariate analyses were performed to identify risk factors using a Cox proportional hazards model. The recurrence-free survival (RFS) rates of the patients with stages T1N2, T1N3, and T3N0 cancer were 80.0, 76.4, and 100% at 5 years, respectively. The only significant prognostic factor for the survival rates of the patients with stage pT1N2-3 cancer measured by univariate and multivariate analyses was pathological tumor diameter. The 5-year RFS rates of the patients with stage pT1N2-3 cancer were 60.0%, when the tumor diameters measured ,30 mm, and 88.9% when the tumor diameters measured .30 mm (P ¼ 0.0248). These data may suggest that pathological tumor diameter is associated with poor survival in patients with small T1N2-3 tumors. Because our study was a retrospective single-center study with a small sample size, a prospective multicenter study is necessary to confirm whether small tumors are risk factor for the RFS in T1N2-3 disease.

show abstract

Surgical Outcomes in Patients with T4 Gastric Carcinoma

Cited by 72 publications

References 10 publications

Prognostic impact of venous invasion in stage IB node-negative gastric cancer

Prognostic impact of venous invasion in stage IB node-negative gastric cancer

The Detection of Messenger RNA for Carcinoembryonic Antigen and Cytokeratin 20 in Peritoneal Washing Fluid in Patients with Advanced Gastric Cancer

Exploratory Analysis to Find Unfavorable Subset of Stage II Gastric Cancer for Which Surgery Alone Is the Standard Treatment; Another Target for Adjuvant Chemotherapy

Contact Info

Product

Resources

About